Related Experiment Video

Updated: Jul 7, 2026

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

Bone morphogenetic protein-7 and connective tissue growth factor: novel targets for treatment of renal fibrosis?

Tri Q Nguyen1, Roel Goldschmeding

  • 1Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.

Pharmaceutical Research
|February 13, 2008
PubMed

Insights

Transforming growth factor-beta1 (TGF-β1) is key in kidney fibrosis, but its blockade is not effective in humans. Bone morphogenetic protein-7 (BMP-7) and connective tissue growth factor (CTGF) show promise for treating kidney fibrosis.

Area of Science:

  • Nephrology
  • Fibrosis Research
  • Regenerative Medicine

Background:

  • Renal fibrosis, a key factor in kidney disease progression, arises from kidney injury.
  • Transforming growth factor-beta1 (TGF-β1) is a primary driver of renal fibrosis, but TGF-β1 blockade has failed in human trials.
  • Exploring alternative therapeutic targets is crucial for managing kidney fibrosis.

Purpose of the Study:

  • To review the roles of bone morphogenetic protein-7 (BMP-7) and connective tissue growth factor (CTGF) in renal fibrosis.
  • To discuss the therapeutic potential of BMP-7 and CTGF in kidney disease.

Main Methods:

  • Literature review of studies on BMP-7 and CTGF in renal fibrosis models and human patients.
  • Analysis of growth factor expression patterns in kidney injury.

Main Results:

  • BMP-7 expression decreases in renal disease, while CTGF expression increases.
  • BMP-7 administration or CTGF inhibition improves renal function and structure in experimental models.
  • BMP-7 and CTGF are identified as novel modulators of TGF-β1 activity.

Conclusions:

  • BMP-7 and CTGF represent promising therapeutic targets for renal fibrosis.
  • Further research into BMP-7 and CTGF could lead to effective treatments for kidney disease.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...